SELENOP and prostate carcinoma: In 2010, in a cohort study of 248 patients diagnosed with prostate cancer and 492 patients in the control group, the risk of developing prostate cancer was 1.72 times higher in patients with known SEPP1 (rs7579) polymorphism, but without statistical significance (p-value 0.22) [49].